期刊文献+

氯法拉滨诱导U937细胞自噬性死亡的机制 被引量:4

Mechanism for Clofarabine Inducing Autophagic Death of Acute Myelocytic Leukemia Cell U937
下载PDF
导出
摘要 本研究旨在探讨氯法拉滨诱导急性髓系白血病(AML)细胞U937自噬性死亡的机制。不同浓度氯法拉滨作用U937细胞24、48 h后,用MTT法计算细胞生长抑制率及氯法拉滨半数抑制浓度(IC50),流式细胞术检测细胞自噬率的变化;Western blot方法检测细胞自噬相关蛋白Beclin 1的表达变化。结果表明,0.01和0.15μmol/L氯法拉滨作用U937细胞48 h,增殖抑制率分别为(46.92±4.24)%和(86.10±1.16)%,IC50为0.022μmol/L,与对照组比较差异有统计学意义(P<0.05)。0.01和0.1μmol/L氯法拉滨作用U937细胞48 h,自噬率分别为(11.0033±1.4387)%和(59.4133±3.5409)%,且呈剂量依赖性增强(r=0.99);随药物浓度的增加,Beclin 1表达逐渐上调,与对照组比较差异有统计学意义(P<0.05)。结论:氯法拉滨对U937细胞有明显的增殖抑制作用,且存在剂量依赖性,其作用机制可能是通过上调Beclin 1的蛋白表达诱导U937细胞自噬性死亡。 To explore the mechanism of autophagic death of acute myelocytic leukemia cell U937 induced by clofarabine, the MTT bioassay was used to analyze the growth inhibitory effect and half inhibition concentration on U937 incubated in vitro with different concentrations of clofarabine for 24 and 48 hours, and the flow cytometry was used to detect the autophagy rate of U937. The expression of Beclin 1 in U937 treated by clofarabine for 48h was meaused by Western blot. The results indicated that when U937 cells were treated with 0.01μmol/L and 0.15 μmol/L clofarabine for48 hours,the proliferation inhibition rate was 46.92% ±4.24% and 86. 10% ± 1. 16%, and the half inhibition concentration of clofarabine was 0.022 μmol/L. With 0.01 μmol/L and 0.1μmol/L clofarabine on U937 for 48 hours, the autophagy rate was 11. 0033% ± 1. 4387% and 59.4133% ± 3. 5409% ,and increased in dose-dependent manner( r = 0.99). Meanwhile the Beclin 1 was upregulated along with increase of clofarabine concentration, as compared with control group, the difference was statistically significant ( P 〈 0.05 ). It is concluded that the different concentrations of clofarabine can significantly inhibit the proliferation of U937 in dose-dependent manner, and the mechanism of autophagic cell death in U937 may be associated with the upregulation of Beclin 1 expression.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2013年第2期347-350,共4页 Journal of Experimental Hematology
关键词 氯法拉滨 急性髓细胞白血病 自噬性死亡 细胞U937 clofarabine acute myelocytic leukemia autophagy U937 cell line
  • 相关文献

参考文献15

  • 1Steinherz PG,Meuers PA,Steinherz LJ,et al. Clofaraine induceddurable complete remission in heavily pretreated adolescents withrelapsed and refractory leukemia. J Pediatr Hematol Oncol,2007 ;29(9) :656-658. 被引量:1
  • 2Gozuacik D,Kimchi A. Autophagy as a cell death and tumorsuppressor mechanism. Oncogene,2004 ; 23( 16) :2891 -2906. 被引量:1
  • 3Biederbick A,Kem HF,Elsasser HP. Monodansylcadaverine(MDC) is a specific in vivo marker for autophagic vacuoles. Eur JCell Biol,1995; 66(1) :3 -14. 被引量:1
  • 4夏敏,蒋慧.儿童急性白血病治疗新药氯法拉滨[J].世界临床药物,2007,28(6):356-359. 被引量:11
  • 5Genini D,Adachi S,Chao Q,et al. Deoxyadenosine analogsinduce programmed cell death in chronic lymphocytic leukemia cellsby damaging the DNA and by directly affecting the mitochondria.Blood,2000;96(10) :3537 -3543. 被引量:1
  • 6Kline JP,Larson RA. Glofarabine in the treatment of acute myeloidleukemia and acute lymphoblastic leukemia:a review. Expert OpinPharmacother,2005 ;6(15) :2711 -2718. 被引量:1
  • 7Zhang Y,Zhang J,Shahriar M,et al. Clofarabine induceshypomethylation of DNA and expression of Cancer - Testisantigens. Leuk Res,2009;33(12) :1678 - 1683. 被引量:1
  • 8路瑾,黄晓军.氯法拉滨在血液系统恶性肿瘤治疗中的应用[J].中华血液学杂志,2010,31(1):66-68. 被引量:2
  • 9Gozuacik D,Kimchi A. Autophagy as a cell death and tumorsuppressor mechanism. Oncogene,2004 ;23 (16) :2891 -2906. 被引量:1
  • 10Scarlatti F,Bauvy C,Ventruti A,et al. Ceramide - mediatedmacroautophagy involves inhibition of protein kinase B and up -regulation of beclin 1. J Biol Chem,2004; 279 ( 18 ) :18384 -18391. 被引量:1

二级参考文献52

  • 1Faded S, Gandhi V, O' Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with evtarabine (ara-C) in relapsed and refraetory acute leukemias. Blood, 2005,105: 940- 947. 被引量:1
  • 2Becker PS, Estey E, Petersdorf S, et al. Phase Ⅰ trial of clofarabine and high dose cytarabine with G-CSF priming (G-CLAC) for relapsed or refractory acute myeloid leukemia. Blood, 2005, 112 : absract 2964. 被引量:1
  • 3Thomas X, Lobe I, Raffoux E, et al. Intensive consolidation with clofarahine and Intermediate-dose cytarabine (CLARA) in patients with high-risk AML in first CR: the ALFA-0702 pilot study. Blood, 2008,112 :absraet 1934. 被引量:1
  • 4Faderl SB, Borthakur G, Ravandi F, et al. Results of a randomized phase 2 study of clofarabine plus cytarabine (CA) vs Clotarabine plus ldarubicin (CI) vs Clofarabine, Idarubicin, plus Cytarabine (CIA) as salvage therapy in acute myeloid leukemia (AML). Blood, 2008,112 :abstract 964. 被引量:1
  • 5Burnett A, Kell W, Hills R, et al. The feasibility of combining daunorubicin, clofarabine and gemtuzumab ozogamicin is feasible and effective. A pilot study. Blood, 2006, 108: abstract 1950. 被引量:1
  • 6Karp JE, Ricklis RM, Balakrishnan K, et al. A phase 1 clinicallaboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood, 2007,110: 1762- 1769. 被引量:1
  • 7Hijiya N, Gaynon PS, Fernandez M, et al. Durable remissions observed in a phase Ⅰ/Ⅱ study of Clofarabine in combination with Etoposide and Cyclophosphamide in pediatric patients with refractory or relapsed acute leukemia. Blood, 2008,112 :abstract 2925. 被引量:1
  • 8Moufarij MA, Sampalh D, Keating M J, et al. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood, 2006,108:4187-4193. 被引量:1
  • 9Burnett A, Russell N, Kell J, et al. A phase 2 evaluation of single agent elofarabine as firsl line treatment fur older patients with AML who are not considered fit for intensive chemotherapy. Blood, 2004,104 : abstract 869. 被引量:1
  • 10Burmett A, Baccarani M, Johnson P, et al. Effectiveness of clofarabine in elderl) AML patients with adverse cytogenetics unfit tor intensive chemotherapy. Blood, 2006,108 : abstract 1985. 被引量:1

共引文献17

同被引文献41

  • 1陈静,顾龙君,应大明.小剂量氨甲蝶呤联合GM-CSF对U973细胞的诱导分化作用[J].上海第二医科大学学报,2004,24(7):538-541. 被引量:1
  • 2Juan Cheng,Jing Chen,Bei Xie,Hu-lai Wei.Acquired multidrug resistance in human K562/ADM cells is associated with enhanced autophagy[J]. Toxicology Mechanisms and Methods . 2013 (9) 被引量:2
  • 3The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy[J]. Immunological Reviews . 2007 (1) 被引量:2
  • 4Andrade-VieiraR, GoguenD, BentleyHA, et al.Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss[J].Oncotarget, 2014, 5(24):12738-12752. 被引量:1
  • 5LeeJH, KangKW, LeeHW.Expression of phosphorylated mTOR and its clinical significances in small cell lung cancer[J].Int J Clin Exp Pathol, 2015, 8(3):2987-2993. 被引量:1
  • 6TekirdagKA, KorkmazG, OzturkDG, et al.MIR181A regulates starvation-and rapamycin-induced autophagy through targeting of ATG5[J].Autophagy, 2013, 9(3):374-385. 被引量:1
  • 7EvangelistiC, EvangelistiC, ChiariniF, et al.Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review)[J].Int J Oncol, 2014, 45(3):909-918. 被引量:1
  • 8WuKN, ZhaoYM, HeY, et al.Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways[J].J Leuk, 2014, 55(3):668-676. 被引量:1
  • 9CaniA, SimioniC, MartelliAM, et al.Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia[J].Oncotarget, 2015, 6(9):6597-6610. 被引量:1
  • 10WangZ, XuF, YuanN, et al.Rapamycin inhibits pre-B acute lymphoblastic leukemia cells by downregulating DNA and RNA polymerases[J].Leuk Res, 2014, 8(8):940-947. 被引量:1

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部